HUTCHMED begins global Phase Ia trial of HMPL-A830 in solid tumors after GSK licensing dealSep 28Trial updateHMPL-A830Hutchmed
HUTCHMED licenses HMPL-A830 to GSK; source cites both $1.295B and $1.185B totalsSep 3Quarterly updateHMPL-A830Hutchmed
HUTCHMED posts H1 2026 revenue of $278.3M as China sales rebound and ATTC pipeline advancesJul 30Quarterly updateHutchmed
Hutchmed registers first-in-human Phase I/IIa trial of HMPL-A830 in solid tumorsJul 22Trial updateHMPL-A830Hutchmed
Sign inSign in